** Brokerage Citi Research says North America’s life science sector struggled in the first half of 2025 as new U.S. funding policies and global tariffs hit tools companies hardest, weakening demand and raising uncertainty, with no clear recovery timeline ** Citi views diagnostics companies as more stable, since they rely less on government or big pharma funding, making them safer investments ** Contract Research Organizations (CROs) are seeing more cancellations and tariff risks- Citi ** Citi upgrades Charles River Laboratories CRL.N to “buy” from "neutral," citing conservative earnings cuts and potential activist support ** Downgrades Illumina ILMN.O to “sell” from "neutral," citing risks from China, government funding, and more competition ** Upgrades Hologic HOLX.O to “buy” from "neutral" due to takeover interest and gradual recovery in breast health ** Shares of ILMN down 3.4%, HOLX up 1.9%, CRL up 2.3%
** As of last close, CRL, HOLX, ILMN down 14.2%, ~10%, 25.7% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。